+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Molecular Cancer Therapeutics"

Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 94 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

The Molecular Cancer Therapeutics market is a subset of the Oncology Drugs market, focusing on treatments that target the molecular mechanisms of cancer. These treatments are designed to target specific molecules or pathways that are involved in the development and progression of cancer. This includes targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and gene therapies, as well as immunotherapies, which use the body's own immune system to fight cancer. These treatments are often used in combination with other treatments, such as chemotherapy and radiation therapy, to provide a more comprehensive approach to cancer treatment. Some of the major players in the Molecular Cancer Therapeutics market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Other companies in the market include Amgen, Celgene, Gilead Sciences, and Johnson & Johnson. Show Less Read more